These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22079360)

  • 1. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.
    Eiriksson L; Wells T; Steed H; Schepansky A; Capstick V; Hoskins P; Pike J; Swenerton K
    Gynecol Oncol; 2012 Mar; 124(3):553-7. PubMed ID: 22079360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
    Abrão RA; de Andrade JM; Tiezzi DG; Marana HR; Candido dos Reis FJ; Clagnan WS
    Gynecol Oncol; 2008 Jan; 108(1):149-53. PubMed ID: 17931696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
    J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
    Zhou Y; Feng FZ; Xiang Y; Wan XR
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
    Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
    J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
    Han SN; Amant F; Leunen K; Devi UK; Neven P; Berteloot P; Vergote I
    Gynecol Oncol; 2012 Oct; 127(1):47-50. PubMed ID: 22705360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
    Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
    Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study.
    Covens A; Filiaci VL; Burger RA; Osborne R; Chen MD;
    Cancer; 2006 Sep; 107(6):1280-6. PubMed ID: 16900525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
    Dobson LS; Lorigan PC; Coleman RE; Hancock BW
    Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
    Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
    Diaz J; Thomas MB; Paz-Pabon C; Hernandez E
    J Reprod Med; 2012; 57(9-10):411-4. PubMed ID: 23091988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
    Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
    J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.